PRS 060

Drug Profile

PRS 060

Alternative Names: PRS-060

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pieris Pharmaceuticals; University of Melbourne
  • Class Antiasthmatics; Lipocalins
  • Mechanism of Action Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 09 Aug 2017 Pieris Pharmaceuticals plans a phase I trial for PRS 060 for Asthma (In volunteers) in Australia in the fourth quarter of 2017
  • 12 Jun 2017 Pieris Pharmaceuticals' collaboration with AstraZeneca gets clearance post-expiration of the Hart-Scott-Rodino Act waiting period
  • 03 May 2017 AstraZeneca enters into a collaboration with Pieris Pharmaceuticals for Respiratory disorders, including Asthma, to develop Anticalin®-based inhaled treatments
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top